Abstracts tagged "autoimmune diseases"

Abstract Number: 1837 • ACR Convergence 2021
KL-6, CXCL11 and CTGF Are Potential Biomarkers in Response to Treatment in CTD-ILD
Yu-Hsiang Chiu¹, Mareye Voortman¹, Eveline Delemarre¹, Stefan Nierkens¹, Pim de Jong¹, Firdaus Mohamed Hoesein¹, Jan Grutters², Jacob van Laar¹ and Julia Spierings³, ¹University Medical Centre Utrecht, Utrecht, Netherlands, ²St. Antonius Hospital, Nieuwegein, Netherlands, ³University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Connective tissue disease related interstitial lung disease (CTD-ILD) is common and an important cause of morbidity and mortality. We aimed to identify biomarkers in…
Abstract Number: 0111 • ACR Convergence 2021
Risk of Hospitalization, Admission to Intensive Care and Mortality Due to COVID-19 in Patients with Rheumatic Diseases: A Population-based Matched Cohort Study
Ana Michelle Avina-Galindo¹, Shelby Marozoff¹, Zahra Fazal¹, Jessie Kwan¹, Na Lu¹, Alison Hoens², Diane Lacaille³, Jacek Kopec⁴, Hui Xie⁵ and J. Antonio Avina-Zubieta³, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada Arthritis Patient Advisory Board, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴University of British Columbia, Richmond, BC, Canada, ⁵Simon Fraser University, Burnaby, BC, Canada
Background/Purpose: New cases of the novel coronavirus disease (COVID-19) continue to occur even one year since the declaration of a global pandemic. Although most people…
Abstract Number: 0315 • ACR Convergence 2021
Sjögren’s Syndrome Symptom Diary (SSSD) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) as Assessments of Symptoms in Sjögren’s Syndrome: A Qualitative Exploration of Content Validity and Meaningful Change
Samantha Wratten¹, Natasha Griffiths², Carl Cooper², Jessica Flynn², Rebecca Hall³, Linda Abetz-Webb², Wolfgang Hueber⁴, Briana Ndife⁵ and Pushpendra Goswami⁴, ¹Adelphi Values, Macclesfield, United Kingdom, ²Adelphi Values, Bollington, United Kingdom, ³Adelphi Values Ltd, Bollington, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis, East Hanover, NJ
Background/Purpose: The aim of this study was to gain qualitative patient feedback on the appropriateness of two Patient Reported Outcome (PRO) measures as assessments of…
Abstract Number: 0534 • ACR Convergence 2021
Lymphatic Dysfunction in Murine Lupus Photosensitivity
William Ambler¹, Noa Schwartz², Jin Yeon Shin³, Rahgu Kataru⁴, Camila Carballo⁵, Scott Rodeo⁶, Babak Mehrara⁴ and Theresa Lu⁷, ¹Division of Pediatric Rheumatology, Department of Rheumatology, Hospital for Special Surgery. HSS Research Institute, Hospital for Special Surgery, New York, NY, ²Department of Medicine, Division of Rheumatology, Albert Einstein College of Medicine, New York, NY, ³Department of Surgery, Division of Plastic and Reconstructive Surgery Memorial Sloan Kettering, New York, NY, ⁴Department of Surgery, Division of Plastic and Reconstructive Surgery, Memorial Sloan Kettering, New York, NY, ⁵HSS Research Institute, Hospital for Special Surgery, New York, NY, ⁶HSS Research Institute, Hospital for Special Surgery; Department of Orthopedics, Hospital for Special Surgery, New York, NY, ⁷Hospital for Special Surgery, New York, NY
Background/Purpose: The lymphatic system is composed of vessels which carry fluid, soluble molecules, and cells from peripheral tissue to draining lymph nodes. Photosensitivity, an exaggerated…
Abstract Number: 0716 • ACR Convergence 2021
Marked Capillary Basement Membrane Reduplication Is the Hallmark Histopathological Feature of Scleromyositis
Benjamin Ellezam¹, Yves Troyanov², Valérie Leclair³, Imane Bersali⁴, Margherita Giannini⁴, Sabrina Hoa⁵, Josiane Bourré-Tessier⁵, Minoru Satoh⁶, Marvin Fritzler⁷, Béatrice Lannes⁸, Jean-Luc Senécal⁵, Marie Hudson⁹, Alain Meyer⁴ and Océane Landon-Cardinal⁵, ¹Division of Pathology, CHU Sainte-Justine; Department of Pathology and Cell Biology, Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Hôpital du Sacré-Coeur; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ³Division of Rheumatology, Jewish General Hospital; Department of Medicine, McGill University, Montréal, QC, Canada, ⁴Service de physiologie- explorations fonctionnelles musculaire, service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg., Strasbourg, France, ⁵Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁶Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷University of Calgary, Calgary, AB, Canada, ⁸Service de Pathologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁹McGill University, Montréal, QC, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subset of autoimmune myositis (AIM) in patients with features of systemic sclerosis (SSc). SM patients may present without characteristic…
Abstract Number: 1039 • ACR Convergence 2021
Healthcare Resource Utilization and Costs of Dermatomyositis and Polymyositis in the United States: A Systematic Literature Review
Rohit Aggarwal¹, Kelly Gwathmey², Richard Leff³, Konrad Pisarczyk⁴, Izabela Aleksanderek⁵, Kiruthi Palaniswamy⁶ and Noreen Henig⁷, ¹University of Pittsburgh, Pittsburgh, PA, ²Virginia Commonwealth University Health system, Richmond, VA, ³Richard L Leff MD LLC, Chadds Ford, PA, ⁴Maple Health Group, Krakow, Poland, ⁵Maple Health Group, Toronto, ON, Canada, ⁶Kezar Life Sciences, Los Angeles, CA, ⁷Kezar Life Sciences, Inc, Foster City, CA
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare heterogenous systemic autoimmune disorders with primary target of muscle, skin, but can also impact multiple other organs.…
Abstract Number: 1391 • ACR Convergence 2021
Rituximab Is Superior to Placebo in Polymyalgia Rheumatica Patients: A Double Blind Randomized Controlled Proof of Principle Trial
Diane Marsman¹, Nathan den Broeder², Frank van den Hoogen³, Alfons den Broeder¹ and Aatke van der Maas⁴, ¹Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands, ²Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands, ³Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ⁴St Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: Corticosteroids remain the cornerstone of polymyalgia rheumatica treatment, but their use has several disadvantages such as long treatment duration and glucocorticoid-related adverse events.1,2 Data…
Abstract Number: 1537 • ACR Convergence 2021
Impact of COVID-19 Infection on Patient-Reported Outcomes in Rheumatic Disease Patients: A Cross Sectional Study
Elaine Husni¹, Cassandra Calabrese², Brittany Lapin¹, Elizabeth Kirchner³ and Leonard Calabrese¹, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland Heights, OH, ³CCF, Cleveland, OH
Background/Purpose: The persistence of symptoms following COVID 19 is an area of great interest yet remains poorly understood. Long COVID symptoms are dominated by fatigue…
Abstract Number: 1689 • ACR Convergence 2021
Safety, Tolerability, Pharmacokinetics, Receptor Occupancy, and Suppression of T-cell-Dependent Antibody Response in a Phase 1 Study with KPL-404, an anti-CD40 Monoclonal Antibody
Manoj Samant¹, Alistair Wheeler², Guang-Liang Jiang¹, Moses Njenga¹, Madeline Spiers¹, Arian Pano¹ and John F Paolini¹, ¹Kiniksa Pharmaceuticals Corp., Lexington, MA, ²Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda
Background/Purpose: T-cell priming and T-cell-dependent B-cell responses require an intact cluster of differentiation (CD)40/CD40L pathway. CD40 is expressed on the surface of B-cells, dendritic cells,…
Abstract Number: 1889 • ACR Convergence 2021
Arthritogenic T Cells Harbor a Transcriptional Program of T Cell Activation and a Repertoire Pruned by Endogenous Superantigen
JUDITH F ASHOURI, Elizabeth McCarthy, Steven Yu, Noah Perlmutter, Charles Lin, Chun Jimmie Yu and Arthur Weiss, University of California San Francisco, San Francisco, CA
Background/Purpose: It is widely accepted that activation of specific CD4 T cells through their TCRs by self-antigen (Ag) is necessary for rheumatoid arthritis (RA) onset.…
Abstract Number: 0114 • ACR Convergence 2021
The Safety Profile of SARS-CoV-2 Vaccines Among Patients with Immune-Mediated Rheumatic Diseases
Jose A Gomez-Puerta¹, Núria Sapena², Juan C Sarmiento-Monroy³, Ana Belén Azuaga¹, Virginia Ruiz-Esquide², Beatriz Frade-Sosa², Marta Bassas², Rosa Morlà², Andrés Ponce², Juan D Cañete¹, Julio Ramirez², Anna Villella⁴, Antoni Trilla⁴ and Raimon Sanmarti⁵, ¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic, Barcelona, Spain, ³Hospital Clinic Barcelona, Barcelona, Spain, ⁴Department of Preventive Medicine and Epidemiology, Hospital Clínic, Barcelona, Spain, ⁵Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: The best strategy for the prevention of SARS-CoV-2 infection is vaccination. Both mRNA and vector vaccines have demonstrated a satisfactory safety profile in general…
Abstract Number: 0316 • ACR Convergence 2021
Exploring Alternative Responder Definitions for EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) for Use in Sjögren’s Clinical Trials
Samantha Wratten¹, Linda Abetz-Webb², Ethan Arenson², Mike Greenwood², Rebecca Hall³, Pip Griffiths⁴, Simon J Bowman⁵, Wolfgang Hueber⁶, Briana Ndife⁷, Daniel Kuessner⁶ and Pushpendra Goswami⁶, ¹Adelphi Values, Macclesfield, United Kingdom, ²Adelphi Values, Bollington, United Kingdom, ³Adelphi Values Ltd, Bollington, United Kingdom, ⁴Former Adelphi Values, Bollington, United Kingdom, ⁵Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis, East Hanover, NJ
Background/Purpose: Sjögren’s is a chronic autoimmune disease symptomatically characterized by dryness, pain and fatigue, which are typically assessed in clinical trials using EULAR Sjögren’s Syndrome…
Abstract Number: 0535 • ACR Convergence 2021
Therapeutic Efficacy of a Biomimetic ALXR Agonist in Murine Systemic Lupus Erythematosus (SLE)
Priyal Dave¹, Tiange Dong¹, Andrew Mead¹, Isaac Asante¹, Brandon Ebright¹, Eugene Zhou¹, RIta Li¹, Nicos Petasis¹, William Stohl² and Stan Louie¹, ¹University of Southern California, Los Angeles, CA, ²University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Neutrophils are key initiators and promoters of autoimmunity, including SLE, via the elaboration of neutrophil extracellular traps (NETs). We tested the efficacy of the…
Abstract Number: 0835 • ACR Convergence 2021
Immunogenicity of Rituximab Biosimilar GP2013 in Chronic Inflammatory Rheumatic Disorders in Daily Clinical Practice
Jerome Avouac¹, Rodolphe Cougnaud-Murail¹, Claire Goulvestre², Sophie Dumas³, Anna Molto⁴, Corinne Miceli-Richard⁵, ornella conort³, Frederic Batteux² and Yannick Allanore¹, ¹Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ²Université de Paris, Service d'Immunologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ³Université de Paris, Service de pharmacie, Hôpital Cochin, AP-HP.CUP, Paris, France, ⁴Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ⁵Assistance Publique Hpitaux de PAris, Paris, France
Background/Purpose: To study in daily practice the risk of immunogenicity of patients treated with rituximab (RTX) biosimilar GP2013 for their chronic inflammatory rheumatic disorder.Methods: A…
Abstract Number: 1040 • ACR Convergence 2021
Monoclonal Gammopathy in Autoimmune Diseases: Analysis and Follow-up of 160 Cases in a Tertiary Center in China
Huazhen Liu, Pengchong Li, Ketian Li, Ziyue Zhou, Lidan Zhao and Xuan Zhang, Peking Union Medical College Hospital, Beijing, China (People's Republic)
Background/Purpose: Monoclonal gammopathy (MG) in patients with autoimmune diseases (AID) is pretty common, but the outcomes and predictors for hematological neoplasm (HN) progression have not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].